Company Description
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1.
The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology.
The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015.
Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Lindsay Androski |
Contact Details
Address: 701 Veterans Circle Warminster, Pennsylvania 18974 United States | |
| Phone | 267 469 0914 |
| Website | arbutusbio.com |
Stock Details
| Ticker Symbol | ABUS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001447028 |
| CUSIP Number | 03879J100 |
| ISIN Number | CA03879J1003 |
| Employer ID | 98-0597776 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lindsay Androski J.D., M.B.A. | President, Chief Executive Officer and Chairman |
| Tuan Nguyen | Chief Financial Officer |
| Andrew J. Sung | General Counsel |
| R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C. | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2025 | 8-K | Current Report |
| May 23, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| May 7, 2025 | 8-K | Current Report |
| Apr 23, 2025 | 8-K | Current Report |
| Apr 21, 2025 | 144 | Filing |
| Apr 15, 2025 | 144 | Filing |
| Apr 4, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2025 | DEF 14A | Other definitive proxy statements |